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5ndothelialization and Late
tent Thrombosis in Diabetics
ith great interest, I read the article by Brar et al. (1) that
etermined whether long-term clinical outcomes differed between
are-metal stents and drug-eluting stents by duration of clopidogrel
se among diabetic patients. The investigators stated, “an in vitro
tudy shows that rapamycin does not seem to impair smooth muscle
igration to the same degree in a hyperglycemic environment
ompared with an euglycemic environment, which might account for
he greater late loss observed in diabetic patients. This might lead to
igher rates of endothelialization and thus lower rates of late stent
hrombosis in diabetic patients.” However, as stated in the editorial as
ell as previous studies (2–4), diabetes is a patient subgroup that is at
he highest risk of stent thrombosis. Higher rates of endothelialization
o not simply translate into lower rates of late stent thrombosis, at
east in diabetics, and do not seem to explain the difference between
his and previous studies as well.
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eply
e thank Dr. Kaneda for his interest and comments regarding our
ecent publication (1). These comments highlight the complexities
nterrelating diabetes and stent thrombosis.
In patients with diabetes, there is generally more severe and
iffuse atherosclerosis, which accounts, in part, for the higher rates
f adverse cardiovascular events. In this setting, it can be difficult
o discern stent thrombosis from plaque rupture within or adjacent
o a stent. On occasion, plaque rupture, strut fracture, or another
tiology for stent thrombosis can be identified by fluoroscopy. These of intravascular ultrasound can provide additional mechanistic
nsight (2). However, the use of intravascular ultrasound is not
niform among studies noting an association between diabetes and
tent thrombosis. Even with a thorough evaluation, misclassifica-
ion of stent thrombosis remains a concern. Therefore, it is not
urprising that a cohort at high risk for coronary events, in
articular plaque rupture, will also be identified as at high risk for
tent thrombosis. This possible misclassification of stent throm-
otic events will create a systematic bias that may inflate the
bserved association between diabetes and stent thrombosis and is
ot amenable to correction or adjustment with multiple regression
odels. Whether after more careful determination of the etiology
f stent thrombosis this association remains is unknown. Newer
maging modalities may help in this evaluation (3).
The clinical implication of the possible association of diabetes
nd stent thrombosis remains unclear. We feel that the risk of stent
hrombosis should be tempered against the marked reduction in
estenosis observed across multiple studies (4,5). Moreover, our
bservations support long-term clopidogrel therapy in this high-
isk cohort and suggest that the best outcomes may be achieved
ith the combination of long-term clopidogrel therapy and use of
rug-eluting stents, manifested as a reduction in myocardial
nfarction or death. A large randomized controlled trial with
ufficient follow-up will be required to definitively answer these
uestions.
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